Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Scientists study a botanical formula that kills aggressive prostate cancer tumors

Scientists at Indiana University, Methodist Research Institute study a botanical formula that kills aggressive prostate cancer tumors. Their findings, based on experiments in mice using a human prostate cancer tumor model, appear online in The International Journal of Oncology.

9 Feb 2012

New, more targeted way to stimulate neurons in the brain

By harnessing quantum dots—tiny light-emitting semiconductor particles a few billionths of a meter across—researchers at the University of Washington (UW) have developed a new and vastly more targeted way to stimulate neurons in the brain.

9 Feb 2012

Link between coronary artery disease and prostate cancer

In a large analysis of men participating in a prostate drug trial, researchers at the Duke Cancer Institute found a significant correlation between coronary artery disease and prostate cancer, suggesting the two conditions may have shared causes.

8 Feb 2012

ACR, AdMeTech and ESUR to expedite development of standards for MR PI-RADS

To improve early diagnosis and treatment of prostate cancer, ACR, AdMeTech Foundation and ESUR have formed a joint effort to expedite development of standards for the Magnetic Resonance Prostate Imaging Reporting and Data System (MR PI-RADS) modeled after a successful effort in breast cancer care

8 Feb 2012

FDA reviews Amgen’s prostate cancer drug Xgeva

U.S. Food and Drug Administration (FDA) researchers say that an Amgen drug slowed the spread of cancer to the bone in men with hard-to-treat prostate cancer, though the drug did not extend life and carried significant side effects.

7 Feb 2012

Spectros 2011 sales revenue increases 69%

Spectros announced today that year-over-year sales revenue rose 69% in 2011. This is the fourth year in a row for double-digit revenue growth for Spectros since the current T-Stat Oximeter was launched in 2008.

7 Feb 2012

New approach can solve treatment-resistant problem in cancers

Free-flowing cancer cells have been mapped with unprecedented accuracy in the bloodstream of patients with prostate, breast and pancreatic cancer, using a brand new approach, in an attempt to assess and control the disease as it spreads in real time through the body, and solve the problem of predicting response and resistance to therapies.

4 Feb 2012

Positive updated results from Aeterna Zentaris' AEZS-108 Phase 1 trial on CRPC

Aeterna Zentaris Inc. today reported positive updated results for the Phase 1 portion of its ongoing Phase 1/2 study in castration- and taxane-resistant prostate cancer (CRPC) with AEZS-108 (zoptarelin doxorubicin), the Company's targeted cytotoxic luteinizing hormone-releasing hormone (LHRH) analog.

4 Feb 2012

Exelixis reports preliminary data from cabozantinib phase 1b trial on RCC

Exelixis, Inc. today reported preliminary data from a cohort of heavily pretreated patients with metastatic refractory renal cell carcinoma (RCC) participating in an ongoing phase 1b trial of cabozantinib.

3 Feb 2012

Urine-based biomarkers may lead to development of test for high-risk prostate cancer

Initial results of a multicenter study coordinated by researchers at Fred Hutchinson Cancer Research Center indicates that two investigational urine-based biomarkers are associated with prostate cancers that are likely to be aggressive and potentially life-threatening among men who take a "watchful waiting," or active-surveillance approach to manage their disease.

3 Feb 2012

NCDB: Five-year survival rates higher among cancer patients treated in SCCA

Five-year survival rates among patients treated by Seattle Cancer Care Alliance for eight types of cancer are higher than for patients treated at other academic medical centers, as well as large and small community cancer centers nationwide, according to data compiled by the National Cancer Data Base (NCDB).

3 Feb 2012

Immune cells from healthy individuals effectively kill cancer cells

Immune cells from healthy individuals can be the new immune cure for cancer. This treatment can kill cancer cells without destroying neighbouring cells. The hope is to eradicate cancer for ever.

3 Feb 2012

Novel PSAV risk count testing may effectively screen men for prostate cancer

A new study by NYU Langone Medical Center and Northwestern University Feinberg School of Medicine shows novel PSA velocity (PSAV) risk count testing may provide a more effective way for physicians to screen men for clinically significant prostate cancer.

3 Feb 2012

EUSA Pharma acquires ASPAREC development and commercialization rights

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that it has acquired the exclusive worldwide development and commercialization rights to ASPAREC for the treatment of acute lymphoblastic leukemia (ALL) from Alizé Pharma.

3 Feb 2012

Gene activity may help explain how vigorous exercise improves survival from prostate cancer

Scientists at the University of California, San Francisco (UCSF) have identified nearly 200 genes in the healthy prostate tissue of men with low-grade prostate cancer that may help explain how physical activity improves survival from the disease.

2 Feb 2012

Cancer Genomics now available online

Genome Research publishes online and in print today a special issue entitled, "Cancer Genomics," highlighting insights gained form cutting-edge genomic and epigenomic analyses of cancer.

2 Feb 2012

Clear link between male subfertility and lower risk of prostate cancer

Involuntary childlessness owing to reduced fertility is a concern for many men. However, these men do have one advantage - they run a significantly lower risk of suffering from prostate cancer. Researchers are interested in whether this phenomenon could be used in the fight against cancer.

2 Feb 2012

Cooked tomatoes could help in prostate cancer: Study

Scientists have discovered the nutrient, lycopene, which is found in cooked tomatoes, can slow the growth and even kill the cancer cells. Dr Mridula Chopra and colleagues at the University of Portsmouth found that lycopene, which gives tomatoes their red color, intercepts the cancer's ability to make the connections it needs to attach to a healthy blood supply.

1 Feb 2012

General anesthesia may lower recurrence risk in patients with HCC

For patients undergoing a minimally invasive treatment for liver cancer, the risk of recurrent cancer appears lower with general anesthesia compared to regional (epidural) anesthesia, reports a study in the February issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

1 Feb 2012

Preliminary results from CINJ's Celebrex and Lipitor Phase II combination trial on prostrate cancer

Research from The Cancer Institute of New Jersey (CINJ) on the FDA-approved drugs Celebrex and Lipitor -- used respectively for arthritis pain and lowering cholesterol -- shows that these drugs are well tolerated in the treatment of recurrent prostate cancer.

1 Feb 2012